Catalent Publishes 2nd Yearly Corporate Accountability Report Highlighting Achievements in an Amazing 12 months for the Pharmaceutical Industry

SOMERSET, N.J.–(Company WIRE)–Catalent, Inc. (NYSE: CTLT), the leading international company of innovative shipping technologies, improvement, and producing methods for medicine, biologics, mobile and gene and therapies, and shopper health and fitness items, currently printed its Corporate Accountability (CR) Report for fiscal year 2020. The report handles environmental, social, and governance (ESG) subject areas appropriate to Catalent’s small business, charting the company’s overall performance towards the Sustainability Accounting Specifications Board (SASB) common for the biotechnology and pharmaceutical industries.

Creating on the foundation laid with Catalent’s initial CR report in 2020 (covering fiscal 2019), which established out aims in regions such as power effectiveness, diversity and inclusion, and group expense, this new report highlights the development made in a 12 months when the enterprise, and the biotechnology and pharmaceutical industries in normal, centered on responding to the global COVID-19 pandemic.

“Our 2020 fiscal year was an terribly hard time period for all people, but it allowed us to reveal the significance of our company accountability determination. At the heart of this motivation is Catalent’s “Patient First” philosophy, which has been elementary to our perform establishing and manufacturing so quite a few COVID-19 vaccines and therapies for buyers as component of the combat versus the all over the world pandemic,” commented John Chiminski, Chair and Chief Government Officer of Catalent. He additional, “I am exceptionally very pleased that, throughout these most complicated of periods, we have continued to prioritize the requires of folks and people, in line with our values and tradition. This, our 2nd company accountability report, carries on to formalize our progress in this region, supporting Catalent’s goal to be the world’s most trustworthy, trustworthy, and impressive drug improvement companion.”

Highlights of the report contain wider sustainability commitments that now include water-effectiveness and waste-reduction targets, and a goal for all web pages to discharge wastewater with API concentrations underneath Predicted No-Outcome Concentration (PNEC) degrees by fiscal 2024. Moreover, 50 assignments focusing on electricity performance at Catalent’s world services were concluded by the close of the 2020 fiscal yr, with 6 Catalent web sites transitioning to 100 {14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} renewable electrical energy sources. In fiscal 2020, the corporation also formulated a human rights statement and expanded its diverse recruiting and expertise growth partnerships. It also set up a well-staying forum and tailored how it communicates with its staff, adopted far more versatile do the job tactics, and enhanced psychological well being and relatives initiatives, in part to account for the consequences of the COVID-19 pandemic on its workforce. The “Catalent Cares” community giving and volunteer plan that was introduced in fiscal 2018 to strengthen employees’ ability to give back to modern society has observed 500 non-revenue businesses gain in fiscal 2020, alongside a quantity of COVID-19 grants produced to communities in need.

The fiscal 2020 Catalent Company Accountability report is offered at, and further details can be requested by calling [email protected]

Notes for Editors

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® organization, is the main worldwide company of highly developed shipping technologies, development, and producing methods for medicine, biologics, cell and gene therapies, and buyer well being products. With in excess of 85 several years serving the sector, Catalent has tested knowledge in bringing extra consumer products to industry quicker, maximizing solution effectiveness and making certain reliable world clinical and professional merchandise source. Catalent employs somewhere around 15,000 persons, such as all around 2,400 researchers and professionals, at a lot more than 45 amenities, and in fiscal calendar year 2020 produced more than $3 billion in yearly profits. Catalent is headquartered in Somerset, New Jersey. For additional data, check out

Extra goods. Improved treatments. Reliably supplied.™

Forward-Hunting Statements

This launch contains both historic and forward-wanting statements. All statements other than statements of historical actuality, are, or may possibly be considered to be, forward-on the lookout statements in just the indicating of Part 27A of the Securities Act of 1933, as amended, and Portion 21E of the Securities Exchange Act of 1934, as amended. These ahead-wanting statements commonly can be recognized by the use of statements that include things like phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would,” or other text or phrases with comparable meanings. Similarly, statements that describe Catalent’s objectives, strategies, or aims are, or may perhaps be, ahead-wanting statements. These statements are centered on present-day anticipations of long run functions. If underlying assumptions establish inaccurate or not known pitfalls or uncertainties materialize, precise outcomes could vary materially from Catalent’s anticipations and projections. Some of the things that could bring about real outcomes to differ consist of, but are not minimal to, the subsequent: the latest or long term results of the COVID-19 pandemic on Catalent’s and its clients’ corporations participation in a really aggressive marketplace and improved competition that may adversely influence Catalent’s organization demand from customers for its offerings, which relies upon in component on its customers’ investigate and growth and the medical and marketplace success of their products and solutions products and other liability challenges that could adversely have an effect on Catalent’s success of operations, fiscal issue, liquidity and money flows failure to comply with existing and upcoming regulatory needs failure to provide high quality offerings to clients could have an adverse result on Catalent’s enterprise and subject matter it to regulatory actions and costly litigation problems supplying the hugely exacting and elaborate services or help required world wide financial, political and regulatory threats to Catalent’s operations inability to improve existing or introduce new know-how or services choices in a timely fashion insufficient patents, copyrights, trademarks and other sorts of intellectual property protections fluctuations in the charges, availability, and suitability of the factors of the merchandise Catalent manufactures, together with lively pharmaceutical ingredients, excipients, obtained factors and uncooked components modifications in industry accessibility or healthcare reimbursement in the United States or internationally fluctuations in the trade level of the U.S. dollar towards other currencies, such as as a outcome of the U.K.’s exit from the European Union adverse tax legislative or regulatory initiatives or issues or changes to Catalent’s tax positions reduction of key staff risks commonly affiliated with data techniques lack of ability to total any foreseeable future acquisitions or other transactions that might complement or broaden its small business or divest of non-strategic corporations or property and problems in efficiently integrating obtained businesses and recognizing expected rewards of this kind of acquisitions hazards connected with timely and productively completing, and appropriately anticipating the foreseeable future need predicted for, cash growth jobs at present amenities, offerings and customers’ goods that could infringe on the intellectual house legal rights of third get-togethers environmental, wellbeing and protection regulations and regulations, which could improve costs and limit functions labor and employment guidelines and regulations or labor troubles, which could enhance prices or final result in operational disruptions supplemental funds contributions needed to fund Catalent’s existing pension options considerable leverage that may well limit its skill to raise added cash to fund operations and respond to adjustments in the financial state or in the business exposure to fascination-level threat to the extent of its variable-charge debt avoiding it from meeting its obligations less than its indebtedness and variations to environmental standards, guidance, or associated technological capabilities that could render it far more pricey or a lot more hard to get to environmental objectives. For a much more detailed discussion of these and other things, see the information less than the caption “Risk Factors” in Catalent’s Once-a-year Report on Type 10-K for the fiscal year finished June 30, 2020, submitted August 31, 2020. All forward-wanting statements discuss only as of the date of this launch or as of the day they are created, and Catalent does not undertake to update any ahead-looking assertion as a outcome of new information and facts or long term gatherings or developments besides to the extent needed by law.